<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03209791</url>
  </required_header>
  <id_info>
    <org_study_id>14-1287</org_study_id>
    <nct_id>NCT03209791</nct_id>
  </id_info>
  <brief_title>Ethanol Induces Skeletal Muscle Autophagy</brief_title>
  <official_title>Mechanisms of Skeletal Muscle Proteolysis With Ethanol Consumption: an Integrated Molecular Metabolic Approach</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Cleveland Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The Cleveland Clinic</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this study we plan to demonstrate that ethanol induces skeletal muscle autophagy to&#xD;
      degrade MAA adducts.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Hypothesis: Ethanol mediated modification of skeletal muscle proteins to form MAA adducts&#xD;
      that in turn induce skeletal muscle autophagy.&#xD;
&#xD;
      Patients with alcoholic steatosis, hepatitis and cirrhosis (n=10 each) will be recruited from&#xD;
      the liver transplant nutrition clinic or the hepatology inpatient service and their body&#xD;
      composition quantified using anthropometry, bioelectrical impedance analysis, CT image&#xD;
      analysis and DEXA if available.&#xD;
&#xD;
      Control Subjects. Controls will be recruited by advertisement. All control subjects will have&#xD;
      a normal clinical history, physical examination, and screening chemistries. They will not&#xD;
      have any significant medical conditions requiring the use of medications. Their nutritional&#xD;
      status within 20% of normal as defined by ideal body weight.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 18, 2015</start_date>
  <completion_date type="Anticipated">December 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Skeletal Muscle Autophagy</measure>
    <time_frame>4 hours</time_frame>
    <description>We will measure Malonyldialdehyde Acetaldehyde protein adducts to see skeletal muscle proteolysis during a one time muscle biopsy</description>
  </primary_outcome>
  <number_of_groups>4</number_of_groups>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Alcoholic Liver Disease</condition>
  <arm_group>
    <arm_group_label>Alcoholic Steatosis</arm_group_label>
    <description>This group will have 10 patients with alcoholic steatosis which is milder disease and muscle biopsies will be performed</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cirrhosis</arm_group_label>
    <description>This group will consist of 10 patients with cirrhosis. We anticipate a 50% difference in these patients and the controls in the autophagy readouts and muscle biopsies will be performed</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Steatohepatitis</arm_group_label>
    <description>This group will have 10 patients with alcoholic steatohepatitis that have more severe necroinflammation in the liver but for a shorter duration of illness and muscle biopsies will be performed</description>
  </arm_group>
  <arm_group>
    <arm_group_label>controls</arm_group_label>
    <description>This group will consist of 10 patients who are healthy and have no liver disease diagnosis and muscle biopsies will be performed</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Biopsies</intervention_name>
    <description>Biopsy will be done on the Vastus Lateralis muscle in all groups</description>
    <arm_group_label>Alcoholic Steatosis</arm_group_label>
    <arm_group_label>Cirrhosis</arm_group_label>
    <arm_group_label>Steatohepatitis</arm_group_label>
    <arm_group_label>controls</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Histologically characterized patients with alcoholic steatosis, hepatitis and cirrhosis&#xD;
        (n=10 each) will be recruited from the liver transplant nutrition clinic or the hepatology&#xD;
        inpatient service and their body composition quantified using protocols already established&#xD;
        by the PI.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Alcoholic liver disease:&#xD;
&#xD;
          -  clinical, biochemical, imaging criteria and liver biopsy where available&#xD;
&#xD;
          -  Age 18 - 65 years old&#xD;
&#xD;
        Controls:&#xD;
&#xD;
          -  Serum liver transaminases (i.e. ALT and AST) 40 IU/L&#xD;
&#xD;
          -  Normal liver ultrasound&#xD;
&#xD;
          -  Age 18 - 65 years old&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        For both groups - alcoholic liver disease and controls:&#xD;
&#xD;
          -  Poorly controlled diabetes mellitus (HbA1C&gt;9.5 g/dl)&#xD;
&#xD;
          -  Untreated Hyper- / hypo- thyroidism&#xD;
&#xD;
          -  Patients on dialysis, renal disease with serum creatinine 1.5 mg/dL&#xD;
&#xD;
          -  Active intravenous drug use&#xD;
&#xD;
          -  History of bowel surgery or gastric bypass surgery&#xD;
&#xD;
          -  Medications known to alter muscle protein metabolism (i.e. corticosteroids, tamoxifen,&#xD;
             high-dose estrogen, testosterone or anabolic steroids)&#xD;
&#xD;
          -  Metastatic disease, Advanced cardiac or pulmonary disease&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Coagulopathy- INR &gt;1.4 and platelet count &lt;80,000/ml.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Srinivasan Dasarathy, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Cleveland Clinic</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Revathi Penumatsa, MPH</last_name>
    <phone>2164450688</phone>
    <email>penumar@ccf.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Annette Bellar, MSLA</last_name>
    <phone>2166365247</phone>
    <email>bellara@ccf.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Cleveland Clinic</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Revathi Penumatsa</last_name>
      <phone>216-445-0688</phone>
      <email>penumar@ccf.org</email>
    </contact>
    <contact_backup>
      <last_name>Annette Bellar</last_name>
      <phone>2166365247</phone>
      <email>bellara@ccf.org</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>April 14, 2017</study_first_submitted>
  <study_first_submitted_qc>July 3, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">July 6, 2017</study_first_posted>
  <last_update_submitted>August 18, 2021</last_update_submitted>
  <last_update_submitted_qc>August 18, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 20, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>The Cleveland Clinic</investigator_affiliation>
    <investigator_full_name>Srinivasan Dasarathy</investigator_full_name>
    <investigator_title>Staff Physician</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Diseases</mesh_term>
    <mesh_term>Liver Diseases, Alcoholic</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

